Although in vitro studies assessing the efficacy of TEAD inhibition in NF2-deficient mesothelioma cells have been described (58), these are limited by the heterogeneous genomic and transcriptomic landscapes associated with cell lines of mixed origins. This evidence concerns the gene NF2 and mesothelioma.